Two authors of the updated AAN guidelines for treatment with botulinum neurotoxin discussed their findings and potential avenues of further research.
The American Academy of Neurology (AAN) presented its updated guidelines on the use of botulinum neurotoxin in the online issue of Neurology. During the AAN Annual Meeting, David M. Simpson, MD, Icahn School of Medicine at Mount Sinai, New York, NY and Mark Hallett, MD, National Institute of Neurological Disorders and Stroke, Bethesda, MD discussed the new guidelines during a press conference.Guideline updates are presented in the following slides. Disorders for which no new evidence was found include essential tremor, hemifacial spasm, and disorders of the voice. Level A indicates strong evidence was found, level B indicates moderate evidence, and level C indicates weak evidence. The guideline authors utilized findings from class I and II studies to prepare their conclusions and recommendations.Reference: AAN Updates Guidelines on Use of Botulinum Toxin for Spasticity, Headache, Other Brain Disorders press conference. AAN Annual Meeting, Vancouver, British Columbia. Apr 17, 2016.